RecruitingPHASE1, PHASE2NCT06162221
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Revolution Medicines, Inc.
- Principal Investigator
- Revolution MedicinesRevolution Medicines
- Intervention
- RMC-6291(drug)
- Enrollment
- 616 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- City of Hope - Duarte, Duarte, California, United States
- City of Hope - Lennar, Irvine, California, United States
- UC Davis, Davis Comprehensive Cancer Center, Sacramento, California, United States
- University of California, San Diego Moores Cancer Center, San Diego, California, United States
- UCSF Medical Center - Mission Bay, San Francisco, California, United States
- Stanford University - Stanford Cancer Institute, Stanford, California, United States
- Georgetown University Medical Center, Washington D.C., District of Columbia, United States
- Boca Raton Clinical Research Associates, Plantation, Florida, United States
- Cancer Specialists of North Florida, Saint Augustine, Florida, United States
- H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit, Michigan, United States
- Intermountain Health - St. Vincent Frontier Cancer Center, Billings, Montana, United States
- Nebraska Cancer Specialist, Grand Island, Nebraska, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06162221 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07224152NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung CancerM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05987956Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- RECRUITINGPHASE2NCT07104630Pulmonary Rehabilitation in Advanced Lung Cancer SurvivorsCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGEARLY PHASE1NCT07274813A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsShanghai Henlius Biotech
- RECRUITINGPHASE1NCT07358806Study to Assess the Effect of OCT-598 in Patients With Advanced Solid TumorsOscotec Inc.
- RECRUITINGPHASE3NCT06686771Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerCanadian Cancer Trials Group
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →